

SABINSA NEWS RELEASE

RESEARCH REVIEW OF CURCUMIN'S IMMUNE BENEFITS BY SABINSA FOUNDER DR. MUHAMMED MAJEED PUBLISHED

East Windsor, NJ (June 2, 2020) – In these uncertain days of the highly contagious coronavirus, the absence of pharmaceutical intervention in the form of drugs or vaccines has pushed scientists to look for clues among safe herbal extract ingredients. A recent peer-reviewed scientific article co-authored by the founder and chairman of Sabinsa, Dr. Muhammed Majeed, along with a galaxy of other scientists, reviews the possible role of curcumin in COVID-19 scenarios with supporting evidence from existing literature.

The compendious review by eight multi-site authors summarizes the results from *in silico* and animal studies of curcumin on viral infections. The coronavirus enters human cells through the ACE2 receptor by attaching its spike protein (S). Curcumin could at least partially prevent that entry as inferred from *in silico* docking studies. A potential inhibitory effect on the main protease of the coronavirus is also reported in an *in silico* study in the literature. The multi-mechanistic modes of action are the forte of curcumin in various types of virus infections. The paper cites several studies wherein curcumin is effective in pulmonary -inflammation, -fibrosis, and -edema. The positive role of curcumin played out under the cytokine storm conditions during viral infections is also discussed. The review touches on the recuperative actions of curcumin on cardiac and kidney functional damage caused by viral infections. Curcumin's role in mitigating the morbid acute respiratory distress syndrome (ARDS) during viral infections, as demonstrated in animal models, is also reviewed. The outstanding antioxidant and anti-inflammatory properties of curcumin are the basis of their activity.

“We are pleased to see this meaningful assemblage of the relevant work on curcumin published at a time when prevention and strong immunity is on the minds of people around the world,” said Dr. Majeed. “While the world anxiously awaits a permanent solution to this pandemic, it’s helpful to understand how safe herbal compounds like curcumin can support healthy immune function.”

The article may be accessed here: Phytotherapy Research 2020 <https://doi.org/10.1002/ptr.6738>.

About Sabinsa

Sabinsa, founded in 1988, is a manufacturer and supplier of herbal extracts, cosmeceuticals, probiotics, minerals, and specialty fine chemicals. The company markets over 100 standardized botanical extracts and employs more than 1000 people worldwide in 12 manufacturing, R&D, sales, and distribution facilities. Process development and product innovation form the focus of the ongoing R&D efforts in the company's research facilities, located in India and the U.S. Products, many of which are both Kosher and Halal, are extensively researched, patented, and supported by hundreds of published clinical studies. Sabinsa's botanical cultivation program totals nearly 40,000 acres to ensure sustainable, fair trade materials are used in these ingredients. For more information, visit sabinsa.com.

Media Contact

Suzanne Shelton

The Shelton Group

Suzanne@SheltonGroupPR.com

Cell: 847-922-5454